NextCure (NASDAQ:NXTC) Major Shareholder Adar1 Capital Management, Llc Acquires 36,303 Shares

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc purchased 36,303 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were bought at an average price of $4.94 per share, with a total value of $179,336.82. Following the completion of the acquisition, the insider owned 722,419 shares of the company’s stock, valued at $3,568,749.86. This trade represents a 5.29% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Thursday, July 30th, Adar1 Capital Management, Llc acquired 292,850 shares of NextCure stock. The shares were bought at an average cost of $4.93 per share, for a total transaction of $1,443,750.50.
• On Wednesday, July 29th, Adar1 Capital Management, Llc acquired 3,410 shares of NextCure stock. The stock was bought at an average price of $5.00 per share, for a total transaction of $17,050.00.
• On Tuesday, July 28th, Adar1 Capital Management, Llc bought 6,400 shares of NextCure stock. The stock was bought at an average price of $4.95 per share, with a total value of $31,680.00.
• On Monday, July 27th, Adar1 Capital Management, Llc bought 7,798 shares of NextCure stock. The stock was bought at an average price of $5.00 per share, with a total value of $38,990.00.

NextCure Stock Up 6.3%

Shares of NASDAQ:NXTC traded up $0.26 during trading on Monday, reaching $4.40. 405,433 shares of the company traded hands, compared to its average volume of 931,919. The firm has a fifty day simple moving average of $3.49 and a 200 day simple moving average of $8.65. NextCure, Inc. has a 1-year low of $1.55 and a 1-year high of $15.74. The firm has a market cap of $15.89 million, a P/E ratio of -0.26 and a beta of 1.42.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.10) by $0.23. As a group, research analysts anticipate that NextCure, Inc. will post -7.89 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Weiss Ratings lowered NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 7th. Zacks Research upgraded NextCure from a “strong sell” rating to a “hold” rating in a report on Thursday, June 11th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of NextCure in a research note on Wednesday, July 15th. Finally, Wall Street Zen downgraded NextCure from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $19.00.

Institutional Investors Weigh In On NextCure

Several institutional investors and hedge funds have recently modified their holdings of NXTC. Cable Car Capital LP boosted its holdings in NextCure by 13.1% in the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock worth $349,000 after purchasing an additional 88,040 shares in the last quarter. Affinity Asset Advisors LLC raised its holdings in NextCure by 28.9% during the fourth quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company’s stock valued at $3,509,000 after buying an additional 55,412 shares in the last quarter. Ikarian Capital LLC acquired a new stake in shares of NextCure in the fourth quarter worth about $3,382,000. Squadron Capital Management LLC acquired a new stake in shares of NextCure in the fourth quarter worth about $3,363,000. Finally, Exome Asset Management LLC acquired a new stake in shares of NextCure in the fourth quarter worth about $2,341,000. Institutional investors and hedge funds own 42.65% of the company’s stock.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.